阿法骨化醇质量控制研究进展  

Research progress on quality control of alfacalcitol

作　　者：郭思瑞 王晶[1] 王月 徐文峰[1] 金鹏飞[1] GUO Sirui;WANG Jing;WANG Yue;XU Wenfeng;JIN Pengfei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部国家老年医学中心、中国医学科学院老年医学研究院、北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《临床药物治疗杂志》2024年第11期26-30,共5页Clinical Medication Journal

基　　金：中央高水平医院临床科研业务费资助(BJ-2021-211);首都卫生发展科研专项(首发2024-1-4052)。

摘　　要：阿法骨化醇作为维生素D_(3)的活性代谢产物,临床主要用于骨质疏松及维生素D代谢异常引发的各类症状,具有起效快、应用范围广、安全性高等特性,随着阿法骨化醇研究的深入,多种剂型得以开发,质量标准不断提高。因此,本研究通过检索PubMed、UpToDate、中国知网、万方数据知识服务平台等数据库,着重从药理作用、质量控制研究和安全性评估进行论述,旨在为研究阿法骨化醇的质量标准奠定基础,提供可靠参考。Alfacalcidol,an active metabolite of vitamin D_(3),is mainly used in clinical practice for various symptoms caused by osteoporosis and abnormal vitamin D metabolism.It has the characteristics of rapid onset,wide application range and high safety.With the deepening of research on alfacalcidol,a variety of dosage forms have been developed,and the quality standards have been continuously improved.Therefore,this study conducted a comprehensive literature review by systematically searching PubMed,UpToDate,CNKI,Wanfang databases and other databases.This review focused on elucidating pharmacological mechanism,the quality control research,and safety of alfacalcidol.The objective was to establish a foundation for further quality standard research of alfacalcitol and provide a reliable reference.

关 键 词：阿法骨化醇 质量控制 质量标准 安全性 

分 类 号：R977.24[医药卫生—药品]